This inventor holds 22 USPTO granted patents and 10 published patent applications. Top assignees: Baxter Travenol Laboratories, Inc., Jenomic, Jenquest. Active years: 1980-2021.
Location History:
- Carmel, CA (US) (1987)
- Houston, TX (US) (1980 - 1992)
- Pebble Beach, CA (US) (1998 - 2021)
Company Filing History:
2 out of 809 
1 out of 1 
1 out of 1 Years Active: 1980-2021
Title: David Stephen Terman: A Trailblazer in Cancer Treatment Innovations
Introduction
David Stephen Terman is a prominent inventor based in Pebble Beach, CA, with a remarkable portfolio comprising 22 patents. His groundbreaking work in the field of cancer treatment has garnered significant attention, showcasing innovative methods aimed at tackling some of the most challenging aspects of cancer therapy.
Latest Patents
One of Terman's latest patents focuses on "Compositions and methods for treatment of cancer," particularly addressing the resistance of randomly dispersed and oxygen-starved lung tumor cells to conventional chemo- and radiotherapy. This innovative approach utilizes sickle cells derived from individuals with sickle cell anemia to specifically target oxygen-deprived tumor cells that often survive and multiply post-treatment. By transfusing these sickle cells, Terman's method occludes tumor microvessels, effectively shutting down the blood flow to oxygen-deprived areas and leading to the death of tumor cells alongside complete shrinkage of aggressive lung tumors.
His research shows that combining sickle cells with vascular disrupting agents and radiation significantly enhances the destruction of tumor blood vessels, amplifying the tumor-killing effect beyond any single agent. This combinatorial treatment represents a major advance in eliminating treatment-resistant tumor cells, thereby reducing the likelihood of lung cancer recurrence.
Another critical patent by David Terman reveals how SEG/SEI presented from a HLA-DQ8 platform can prevent the de novo outgrowth of Lewis lung carcinoma and B16-F10 melanoma while also retarding the growth of established tumors without significant toxicity. In studies involving DQ8 tg mice, vaccination followed by SEG/SEI immunization resulted in extraordinary survival rates, with some mice surviving for 200 days compared to a mere 20 days for untreated controls.
Career Highlights
Terman’s impressive career includes significant affiliations with esteemed institutions and organizations, including Baxter Travenol Laboratories, Inc. His innovative spirit has been the driving force behind numerous advancements in cancer treatment methodologies, reflecting his dedication to medical research and patient outcomes.
Collaborations
Throughout his career, David Terman has collaborated with notable individuals in the field, such as Herbert M. Cullis and Jay L. Stone. These partnerships have played a vital role in fostering innovative ideas and ensuring that groundbreaking research reaches its potential in transforming cancer treatment.
Conclusion
David Stephen Terman has made significant contributions to the field of cancer research through his innovative patents and treatments. His dedication to developing effective therapies for cancer patients demonstrates the profound impact that one inventor can have in addressing complex medical challenges.